211 related articles for article (PubMed ID: 17028508)
1. Safety and tolerability of methylphenidate in preschool children with ADHD.
Wigal T; Greenhill L; Chuang S; McGOUGH J; Vitiello B; Skrobala A; Swanson J; Wigal S; Abikoff H; Kollins S; McCRACKEN J; Riddle M; Posner K; Ghuman J; Davies M; Thorp B; Stehli A
J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1294-1303. PubMed ID: 17028508
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Childress AC; Marraffino A; Cutler AJ; Oh C; Brams MN
J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):51-58. PubMed ID: 36809150
[No Abstract] [Full Text] [Related]
9. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
[TBL] [Abstract][Full Text] [Related]
11. Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
Becker SP; Froehlich TE; Epstein JN
J Dev Behav Pediatr; 2016 Jun; 37(5):395-404. PubMed ID: 27011002
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
13. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
14. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Greenhill L; Kollins S; Abikoff H; McCracken J; Riddle M; Swanson J; McGough J; Wigal S; Wigal T; Vitiello B; Skrobala A; Posner K; Ghuman J; Cunningham C; Davies M; Chuang S; Cooper T
J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1284-1293. PubMed ID: 17023867
[TBL] [Abstract][Full Text] [Related]
16. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder.
Joshi G; DiSalvo M; Wozniak J; Ceranoglu TA; Yule A; Surman C; Fried R; Galdo M; Hoskova B; Belser A; Biederman J
World J Biol Psychiatry; 2020 Apr; 21(4):274-290. PubMed ID: 31607204
[No Abstract] [Full Text] [Related]
17. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
19. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
Maayan L; Paykina N; Fried J; Strauss T; Gugga SS; Greenhill L
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):147-53. PubMed ID: 19374023
[TBL] [Abstract][Full Text] [Related]
20. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
